Biohit Oyj BIOBV.HE · EUR

Its shares trade on Nasdaq Helsinki under the ticker BIOBV.HE. It has been listed since 18 June 1999. In the fiscal year to 31 December 2025, it reported revenue of €15.7m and net income of €2.7m. At that date it held total assets of €19.8m and shareholders' equity of €14.9m.

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Lea PaloheimoIndependent Chairman of the Board
• Mr. Jussi HahtelaChief Executive Officer, Member of the Management Board
• Mr. Jussi SorvoChief Financial Officer, Member of the Management Board
• Mr. Franco AiolfiDirector, Managing Director of Biohit Healthcare S.r.l., since 2013€15,000
• Mr. Graham JohnsonManaging Director of Biohit Healthcare Ltd.
• Mr. Panu HendolinHead - Research & Development, Member of the Management Board
• Mr. Ilari PatrakkaSales and Marketing Director, Member of the Management Team
• Ms. Annika AstolaQuality Director, Member of the Management Team
• Suvi ElomaaProduction Manager, Member of the Management Board
• Ms. Daniela SoderstromQuality and Regulatory Affairs Director, Member of the Management Team
• Mr. Liu FengDirector
• Prof. Osmo SuovaniemiDirector, since 2022€16,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.